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Summary
Objective:  To assess the clinical outcome of renal transplant patients who developed coronary artery disease and were 
treated with coronary stenting (TCA-ST).
Methods:$ WRWDORIUHQDO WUDQVSODQWVZHUHSHUIRUPHG LQRXUVHUYLFH²Hospital do Rim e Hipertensão²+5+
.LGQH\DQG+\SHUWHQVLRQ+RVSLWDOIURP-XO\WR1RYHPEHU'XULQJWKLVSHULRGRIWKHUHQDOWUDQVSODQW
SDWLHQWVXQGHUZHQW7&$67WRWUHDWVHYHUHVWHQRVHVLQFRURQDU\DUWHULHV$UHWURVSHFWLYHDQDO\VLVZDVSHUIRUPHG
ZLWKUHQDO WUDQVSODQWSDWLHQWVXQGHUJRLQJ7&$67DW+5+7KHFOLQLFDOHYHQWVZHUHUHJLVWHUHGXVLQJPHGLFDOFKDUWV
medical visits and phone calls. 
Results:'XULQJWKHPRQWKFOLQLFDOIROORZXSDIWHU7&$67RIWKHSDWLHQWVUHPDLQHGDV\PSWRPDWLFSUHVHQWHG
VWDEOHDQJLQDSUHVHQWHGDFXWHFRURQDU\V\QGURPHZLWKRXW67VHJPHQWHOHYDWLRQ$&6:67(DQGSUHVHQWHG
DFXWHFRURQDU\V\QGURPHZLWK67VHJPHQWHOHYDWLRQ$&667(1RVWURNHV&+)RUFDUGLDFGHDWKVZHUHREVHUYHG7KUHH
QRQFDUGLDFGHDWKVRFFXUUHG$UHVWHQRVLVUDWHRIZDVREVHUYHGZKLFKLVFRPSDUDEOHWRWKRVHIRXQGLQVWXGLHVRQ
drug-eluting stents.
Conclusion: In conclusion, renal transplant patients who developed CAD and were treated with coronary stenting had a 
low rate of in-stent restenosis, probably related to the immunosuppressive regimen given to prevent kidney rejection.
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Introduction
Two hundred seventy five thousand patients with chronic 
renal failure (CRF) undergoing dialysis were registered in the 
United States, from 1997 to 1999, with 239 deaths/1000 
patients/year. Cardiovascular diseases were the cause of death 
in 44% of the cases. In the same period, 107 thousand renal 
transplant patients were registered. Mortality in this population 
was 34 deaths/1000 patients/year, of which 41% resulted from 
cardiovascular diseases. The lower mortality in transplant 
patients is related to factors such as selection of patients at a 
lower risk for transplantation and risk reduction resulting from 
the transplantation itself. It is important to observe that despite 
the lower mortality of transplant patients when compared to 
that of patients undergoing dialysis, cardiovascular diseases 
remain the main cause of death1-5.
Patients with CRF associated with diabetes mellitus have 
a higher risk of death of 70% in 7 years5-7. It is worth pointing 
out that the majority of patients with CRF present associated 
diabetes mellitus.
CRF patients undergoing stent angioplasty present a 2.2-
fold higher need for repeated target vessel revascularization 
when compared to non-CRF patients (35% versus 16%)8,9.
CRF is a predictor of in-stent restenosis, with an angiographic 
restenosis rate after balloon angioplasty of approximately 60 
to 81%10,11 and clinical restenosis rate after stent implantation 
of approximately 10 to 50%12,13,14.
The use of cyclosporine in experimental studies has 
demonstrated inhibition of smooth muscle cell proliferation 
in response to vascular injury15,16. The use of prednisone 
in patients undergoing angioplasty and who had high CRP 
levels demonstrated a reduction of clinical events and of 
angiographic restenosis17.
Using intracoronary ultrasound, we have previously 
demonstrated a minimal in-stent intimal hyperplasia 
in the group of renal transplant patients using routine 
immunosuppressive regimen18.
Data on the clinical course, clinical restenosis rates, and 
progression of the coronary artery disease (CAD) in this 
population of renal transplant patients undergoing coronary 
angioplasty with stenting (TCA-ST) are not available in the 
literature.
The objective of this study was to assess the clinical course 
of renal transplant patients with CAD, undergoing TCA-ST. 
The following cardiovascular events were considered in the 
clinical course: clinical restenosis, acute coronary syndrome 
with ST-segment elevation (ACSSTE), acute coronary syndrome 
without ST-segment elevation (ACSWSTE), stroke, congestive 
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transplantation and coronary stenting of 37 months (ranging 
from three days to 121 months) were included. Demographic 
characteristics of these patients are shown in Table 1.
All patients were using aspirin and thienopyridine derivatives 
routinely for at least three days prior to stent implantation. 
Aspirin was maintained continuously, and thienopyridine 
derivatives for at least 30 days after TCA-ST (Table 2). 
The median dialysis time until renal transplantation was 12 
months, ranging from patients who did not undergo dialysis 
to those who underwent dialysis for 84 months. 
Fifty five percent of the patients received renal transplants 
from living donors. 
Immunosuppression regimen was distributed as follows: 
90% prednisone, 70% cyclosporine, 64% azathioprine, 33% 
mycophenolate mofetil, and 12% tacrolimus.
Indications for coronary angioplasty were: ACSWSTE in 
67%, ACSSTE in 18%, and stable angina in 15%. 
All stents were successfully implanted and all patients 
were discharged with no complications within 48 hours 
of the procedure. A mean of 1.88 ± 1.11 stents/patient 
were implanted. 
The median clinical follow-up period was 30 months 
(ranging from six months to 82 months).
A favorable clinical outcome was observed, with 67% of 
the patients remaining asymptomatic, 18% remaining with 
stable angina, 6% presenting ACSWSTE, and 3% presenting 
ACSSTE.
No patients with stroke were observed after the procedure. 
heart failure (CHF), and death.
Methods
A total of 3,334 renal transplants were performed in our 
service, Hospital do Rim e Hipertensão (HRH) from July, 1998 
to November, 2004 (Figure 1). During this period, 33 of the 
renal transplant patients underwent TCA-ST to treat 62 severe 
stenoses in 54 coronary arteries. 
A retrospective analysis of the renal transplant patients 
routinely using conventional immunosuppression with 
cyclosporine, azathioprine, prednisone, mycophenolate 
mofetil, or tacrolimus, and who had undergone TCA-ST was 
performed at HRH.
Patients using oral rapamycin, patients who used drug-
eluting stents, patients undergoing TCA-ST prior to renal 
transplantation, and those with unavailable clinical follow-up 
were not included.
The clinical events were registered using medical charts, 
medical visits and phone calls. 
Demographic characteristics, risk factors for cardiovascular 
diseases, immunosuppressive drugs used, cardiovascular 
drugs used by the time of angioplasty, dialysis time prior to 
transplantation, the type of donor, number of stented coronary 
arteries, number of stents implanted, and the clinical course 
for at least six months after TCA-ST were analyzed. 
Patients underwent repeat cardiac catheterization when 
presenting symptoms of CAD, or when presenting a non-
invasive test positive for myocardial ischemia. 
Results
A total of 33 patients with a median time between renal 
Fig. 1 - Number of renal transplants per year at HRH.
Table 1- Clinical characteristics of the population
Mean age \HDUV
Male gender 88%
Systemic hypertension 96%
Diabetes mellitus* 45%
Smoking 42%
Dyslipidemia 58%
Family history of cardiovascular 
disease 45%
ZHUHWDNLQJLQVXOLQ
Table 2- Medication used by the time of TCA-ST
Aspirin 100%
Thienopyridine derivatives 100%
Beta blocker 79%
Diuretics 36%
Calcium channel blocker 30%
Angiotensin converting enzyme inhibitor 39%
Statin 36%
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No cardiac deaths occurred. Three non-cardiac deaths 
occurred: two deaths due to urinary sepsis, and one death 
due to colon adenocarcinoma. 
Three patients presented clinical restenosis, defined as an in-
stent stenosis of more than 50% in a patient undergoing repeat 
coronary angiography, and obtaining a rate of 9%. In the analysis 
of restenosis by stent implanted, five stents with restenosis in 62
stents implanted were observed, with a rate of 8%.
Ten patients presented coronary artery disease progression, 
defined as stenosis > 50% in another site not approached by 
coronary angioplasty, and obtaining a rate of 30% (Figure 2).
Discussion
A low rate of 9% clinical restenosis was found for this 
population at a high risk for restenosis: renal transplant 
patients, 45% of whom with diabetes mellitus, most of them 
taking insulin, and a high mean of 1.88 ± 1.11 stents per 
patient. These results are similar to the clinical restenosis rates 
of studies on drug-eluting stents in diabetic patients19. The use 
of a great number of stents per patient is similar to the use of 
approximately two stents per patient demonstrated in recent 
studies with drug-eluting stents in multivessel disease20.
Most of the patients undergoing TCA-ST remained 
asymptomatic, and few major cardiovascular events occurred. 
A low percentage of coronary disease progression was 
observed, probably because of the short follow-up period of 
some patients in this case series of 33 patients. 
The study limitations were: 
- Not all patients underwent coronary angiography, because 
it would not be ethical to make asymptomatic patients undergo 
a repeat invasive procedure.
- Serum level of immunosuppressors is not available 
for all patients, thus not allowing for a correlation with 
restenosis rates. 
- Due to the small number of patients, statistical power was 
not achieved to determine which immunosuppressor had the 
highest impact on the reduction of clinical restenosis.
- This is an observational retrospective study whose 
objective was to perform a clinical analysis of the patients, and 
other mechanism and surrogate variables, such as reference 
vessel diameter, stenosis length, stent length per patient, 
minimum lumen diameter, and acute lumen gain or late lumen 
loss were not assessed.
Conclusion
Renal transplant patients who developed coronary artery 
disease and were treated with stent implantation presented 
a low percentage of clinical restenosis, probably related to 
the immunosuppressive regimen used to prevent kidney 
rejection.
7DEOH&OLQLFDOFRXUVHIROORZLQJVWHQWLPSODQWDWLRQ
Asymptomatic 64%
Stable angina 18%
ACSWSTE 6%
ACSSTE 3%
Death 9%*
* Two patients with urinary sepsis and one with sigmoid 
adenocarcinoma.
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